Latest Breaking News On - Artiva biotherapeutics - Page 7 : comparemela.com

Published June 9, 2021 National Institutes of Allergy and Infectious Diseases. (2016). Human natural killer cell [Micrograph]. Retrieved from Flickr. Dive Brief: Beigene, a fast-growing drugmaker based in Cambridge, Massachusetts and Beijing, will partner with Shoreline Biosciences to develop cell therapies for cancer, expanding its research beyond the small molecule and antibody drugs with which it s had success.  Under a deal announced Wednesday, Beigene and Shoreline will work together to design cancer treatments based on what are known as natural killer cells, one of several types of immune defenders that biotech companies are using to attack tumors.  Beigene will pay $45 million to Shoreline, which could earn more if certain milestones in testing are achieved. Per deal terms, Beigene will also get an option to acquire an equity stake in Shoreline as part of the company s next fundraising. 

United kingdomUnited statesWilliam sandbornJohnv oylerKleanthis xanthopoulosDan kaufmanSteven holtzmanArtiva biotherapeuticsUniversity of california san diegoDive briefShoreline biosciencesCalifornia san diegoNkarta therapeuticsClinical trialsஒன்றுபட்டது கிஂக்டம்ஒன்றுபட்டது மாநிலங்களில்